scispace - formally typeset
S

Sergei Pourmal

Researcher at University of California, San Francisco

Publications -  16
Citations -  956

Sergei Pourmal is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Chemistry & Biology. The author has an hindex of 7, co-authored 10 publications receiving 481 citations. Previous affiliations of Sergei Pourmal include University of California, Berkeley.

Papers
More filters
Journal ArticleDOI

Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms.

David E. Gordon, +203 more
- 04 Dec 2020 - 
TL;DR: The authors identified shared biology and host-directed drug targets to prioritize therapeutics with potential for rapid deployment against current and future coronavirus outbreaks, and found that individuals with genotypes corresponding to higher soluble IL17RA levels in plasma are at decreased risk of COVID-19 hospitalization.
Posted ContentDOI

CryoEM and AI reveal a structure of SARS-CoV-2 Nsp2, a multifunctional protein involved in key host processes.

TL;DR: In this paper, an atomic model for full-length SARS-CoV-2 protein Nsp2 was obtained by combining cryo-electron microscopy with deep learning-based structure prediction from AlphaFold2.
Posted ContentDOI

An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation

TL;DR: Single-domain antibodies (nanobodies) are developed that potently disrupt the interaction between the SARS-CoV-2 Spike and ACE2, promising to yield a widely deployable, patient-friendly prophylactic and/or early infection therapeutic agent to stem the worst pandemic in a century.
Posted ContentDOI

An ultra-potent synthetic nanobody neutralizes SARS-CoV-2 by locking Spike into an inactive conformation

TL;DR: In this article, single-domain antibodies (nanobodies) are developed that potently disrupt the interaction between the SARS-CoV-2 Spike and ACE2, which may enable aerosol-mediated delivery of this potent neutralizer directly to the airway epithelia, promising to yield a widely deployable, patient-friendly and/or early infection therapeutic agent to stem the worst pandemic in a century.